Kelonia Therapeutics reported early clinical data showing efficacy for its in‑vivo CAR‑T approach in multiple myeloma, with single‑infusion results producing deep responses in a small cohort. The company presented data at ASH and highlighted the potential of in‑body programming of patient T cells as a way to simplify manufacturing and broaden access. The readout contributed to a wider field reaction about in‑vivo CAR‑T platforms, with analysts and attendees noting the competitive landscape now includes multiple approaches seeking to match the potency of ex vivo autologous CAR‑T while reducing cost and complexity. Kelonia’s data remain early and will require larger, controlled studies to determine durability and safety across broader populations. Clarification: In‑vivo CAR‑T programs aim to program patient immune cells directly inside the body rather than engineering cells in manufacturing facilities outside the body.